The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation
Author
Reilly, ChristopherRaja, Anandavelu
Anilkumar, Pillai
Sullivan, Julie
White, Lisa
Bahron, Ali
Marsh, Julie
Mansur, Adel H
Affiliation
University Hospitals BirminghamPublication date
2023-12-13Subject
Respiratory medicine
Metadata
Show full item recordAbstract
a total of 66 patients initiated on mepolizumab with a median follow-up of 45.8 (42.4,48.1) months were included in the study [mean age 50.3 years (range 18-79), females 50 (73%) ]. At 20.7 months of treatment, 42 patients (63.6%) had positive response, 13 (19.7%) negative response, and 11 (16.7%) discontinued due to other factors. At 45.8 months, 35 (53%) patients were still on mepolizumab, 21 (31.8%) switched to a different biologic, and 10 (15.2%) discontinued biologics. Two deaths were recorded during the study period.The median blood eosinophil was reduced from 0.43x109/L (0.27, 0.75) to 0.04 (0.0, 0.1) (p < 0.00001)]. The median annual exacerbations were reduced from 6.0 (4,8) to 1.0 (0.0,3.0) (p < 0.00001), and mOCS use was reduced from59% to 29%, p = 0.001. The mean asthma control questionnaire-6 (ACQ6) improved from 3.1 ± 1.7 to 2.1 ± 1.3 (p < 0.00001).Citation
Reilly C, Raja A, Anilkumar P, Sullivan J, White L, Bahron A, Marsh J, Mansur AH. The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation. J Asthma. 2024 Jun;61(6):561-573. doi: 10.1080/02770903.2023.2294908.Type
ArticlePMID
38088937Journal
The Journal of AsthmaPublisher
Informa Healthcareae974a485f413a2113503eed53cd6c53
10.1080/02770903.2023.2294908